You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》先聲藥業(02096.HK)公開超購588倍及上限定價 一手中籤率僅5%
阿思達克 10-23 09:29
內地生物化學製藥集團先聲藥業(02096.HK)公布招股結果,計劃發售2.61億股新股,公開發售錄超購588.47倍,經重新分配後,公開發售股數增至50%,國際發售項下初步提呈發售的發售股份獲超額認購約23倍;一手1,000股中籤率僅為5%。該股將於下周二(10月27日)上市。摩根士丹利及中金為聯席保薦人。

每股發售價定於13.7元,為上限定價(招股價介乎12.1至13.7元),是次上市公司引入7名基石投資者,包括HillhouseCapital、紅土及高新等,合共認購1.07億股股份。

先聲藥業預計所得款項淨額將約為33.92億元,當中60%將用於持續研發在戰略重點治療領域中選定的在研產品;10%將用於加強集團銷售及營銷能力;10%將用於未來幾年投資醫藥或生物技術領域的公司;10%將用於償還若干未償還銀行貸款;餘下10%為營運資金及其他一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account